Execs On The Move, July-August 2014
Executive Summary
Recent executive-level company changes and promotions in the biopharma, medical device, and diagnostics industries.
You may also be interested in...
Hedge Fund Seeks Higher Price For Qiagen As COVID-19 Boosts Sales
Hedge fund Davidson Kempner advised Qiagen to ask for a higher acquisition price from Thermo Fisher Sciences as COVID-19 has increased demand for diagnostic products.
Medtronic/Tandem Patent Agreement Paves Way For Diabetes Product Development
Tandem Diabetes Care and Medtronic have signed a patent cross-license agreement that paves the way for joint development of future diabetes products and services while avoiding potential legal disagreements.
GDUFA Sees First-Ever Fee Spending Decrease
Thanks in part to budget authority bump, US FDA’s generic user fee revenue spending dropped in FY 2019, and hiring problems lead to an FTE decrease. The useable GDUFA carryover balance also increased in conjunction with the user fee revenue spending reduction, from $158.7m available at the end of FY 2018 to $199.2m at the end of FY 2019.
Need a specific report? 1000+ reports available
Buy Reports